≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback

Malignant neoplasm of pyriform sinus, including Hilmo

Endpoint Browser PheWeb

C3_PIRIFORMSINUS_WIDE

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

557745

1. Apply sex-specific rule

None

557745

2. Check conditions

None

557745

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — C12&
  • Hospital discharge: ICD-9 — 1481A
  • Hospital discharge: ICD-8 — 1481
  • Cause of death: ICD-10 — C12&
  • Cause of death: ICD-9 — 1481A
  • Cause of death: ICD-8 — 1481
  • Cancer registry: Topography ICD-O-3 — C12
  • Cancer registry: Morphology ICD-O-3 — ANY
  • Cancer registry: Behaviour codes — 3

3 out of 7 registries used, show all original rules.

54

4. Check minimum number of events

None

54

5. Include endpoints

None

54

6. Filter based on genotype QC (FinnGen only)

50

Control definitions (FinnGen only)

Control exclude
C3_CANCER, C3_CANCER_WIDE

Extra metadata

First used in FinnGen datafreeze
DF12

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

This endpoint is excluded (different definition than used in FinnGen).

-FinnGen-

Key figures

All Female Male
Number of individuals 50 7 43
Unadjusted period prevalence (%) 0.02 0.00 0.02
Median age at first event (years) 67.60 60.87 68.70

-FinnGen-

Age distribution of first events

-FinnGen-

Year distribution of first events

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
51
Matched controls
510
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
C12
ICD-10 Finland
Malignant neoplasm of piriform sinus
+∞
57.7
44
*
130
Kela drug reimbursment
Malignant tumour
+∞
41.4
34
*
WF002
NOMESCO Finland
Radical radiotherapy
+∞
27.6
24
*
504
Kela drug reimbursment
Conditions requiring daily forced enteral nutrition
472.7
27.5
25
*
JDB10
NOMESCO Finland
Percutaneous gastrostomy
437.5
26.2
24
*
A03FA01
ATC
metoclopramide; systemic, rectal
18.7
25.0
27
29
UJC01
NOMESCO Finland
Scopy of lower throat
101.4
22.2
23
*
8070/3-C12.9
ICD-O-3
Squamous cell carcinoma, NOS, of pyriform sinus
+∞
20.1
18
*
WB103
NOMESCO Finland
Simple adjuvant cytostatic therapy
+∞
17.7
16
*
WZC30
NOMESCO Finland
Teaching
11.0
15.4
22
33
GDA98
NOMESCO Finland
Other bronchoscopic incision, excision of lesion or repair of lung
103.5
14.5
15
*
WZC20
NOMESCO Finland
Multidisciplinary treatment meeting
103.5
14.5
15
*
C13.9
ICD-10 Finland
Malignant neoplasm: Hypopharynx, unspecified
+∞
14.2
13
*
N02AA05
ATC
oxycodone; systemic
9.0
13.6
24
46
XX3DW
NOMESCO Finland
Time consuming IT work
35.3
13.6
17
7
UJC02
NOMESCO Finland
Rigid oesophagoscopy
94.0
13.3
14
*
WZC00
NOMESCO Finland
Treatment plan or consultation
7.7
12.3
30
80
UDH02
NOMESCO Finland
Rhinopharyngoscopy
22.5
11.3
16
10
H02AB02
ATC
dexamethasone; systemic
76.6
11.2
12
*
A04AA01
ATC
ondansetron; systemic, rectal
51.0
10.5
12
*
N02AB03
ATC
fentanyl; nasal, sublingual, transdermal
+∞
9.7
9
*
D10.7
ICD-10 Finland
Benign neoplasm: Hypopharynx
+∞
9.7
9
*
JN5DR
NOMESCO Finland
PET-CT of upper body metabolism
60.8
9.0
10
*
EN1BD
NOMESCO Finland
Very extensive CT examination of mouth and soft tissues of neck
107.0
8.7
9
*
A04AA02
ATC
granisetron; systemic, transdermal
+∞
8.6
8
*
JCA55
NOMESCO Finland
Endoscopic dilatation of oesophagus
+∞
8.6
8
*
A06AD11
ATC
lactulose; oral
6.1
8.3
19
45
EB1HA
NOMESCO Finland
Panorama tomography of teeth and jaws or similar X-ray examination
5.0
7.6
31
120
8070/3-C13.9
ICD-O-3
Squamous cell carcinoma, NOS, of hypopharynx, NOS
+∞
7.5
7
*
C77.0
ICD-10 Finland
Secondary and unspecified malignant neoplasm: Lymph nodes of head, face and neck
+∞
7.5
7
*
A04AA55
ATC
palonosetron, combinations; systemic
+∞
7.5
7
*
UDQ12
NOMESCO Finland
Flexible laryngoscopy
12.0
7.3
13
14
EP1AE
NOMESCO Finland
Neck ultrasound examination
17.0
7.3
11
8
EP1CG
NOMESCO Finland
Extensive MRI examination of soft tissue of neck with high intesity magnet
46.4
7.0
8
*
JN4AD
NOMESCO Finland
Body CT examination
10.5
6.8
13
16
QAE10
NOMESCO Finland
Excision of other lesion extending through all layers of skin in head or neck
79.4
6.6
7
*
UDQ22
NOMESCO Finland
Microlaryngoscopy
79.4
6.6
7
*
Z51.5
ICD-10 Finland
Palliative care
10.8
6.5
12
14
R4190
NOMESCO Finland
Nutritional therapy
30.9
6.4
8
*
EBA15
NOMESCO Finland
Extraction of multiple teeth
15.1
6.4
10
8
L01BC06
ATC
capecitabine; oral
+∞
6.4
6
*
C13.1
ICD-10 Finland
Malignant neoplasm: Aryepiglottic fold, hypopharyngeal aspect
+∞
6.4
6
*
UJC12
NOMESCO Finland
Flexible oesophagoscopy
+∞
6.4
6
*
C61
ICD-10 Finland
Malignant neoplasm of prostate
+∞
6.4
6
*
YA1AD
NOMESCO Finland
CT examination of head and neck for dose design of radiotherapy
+∞
6.4
6
*
D38.0
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Larynx
+∞
6.4
6
*
8070/3-C32.9
ICD-O-3
Squamous cell carcinoma, NOS, of larynx, NOS
+∞
6.4
6
*
C13.8
ICD-10 Finland
Malignant neoplasm: Overlapping lesion of hypopharynx
+∞
6.4
6
*
D14.1
ICD-10 Finland
Benign neoplasm: Larynx
+∞
6.4
6
*
UJF32
NOMESCO Finland
Coloscopy
4.5
6.2
21
68
JN4BD
NOMESCO Finland
Extensive body CT
11.3
6.1
11
12

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
20
14
22.54
13.76
1.7
1.1
—
—
—
0
0
18
29
8.98
8.21
3.0
2.6
0.19
0.20
g/l
0.17
18
20
31
120
5.04
7.55
4.1
2.0
—
—
—
0
0
28
107
4.59
6.77
3.7
1.6
—
—
—
0
0
34
171
3.96
5.24
4.0
2.4
—
—
estimate
—
0
0
24
122
2.83
3.21
5.0
3.5
—
—
—
0
0
30
174
2.76
3.08
10.1
4.0
33.19
35.17
g/l
1.12
30
159
11
34
3.84
2.95
1.6
1.1
—
—
—
0
0
17
77
2.81
2.75
7.3
2.2
2.50
2.44
mmol/l
0.95
17
71
9
25
4.14
2.73
4.7
2.8
—
—
—
0
0
35
231
2.64
2.62
26.2
15.4
1.37
1.35
inr
0.04
30
185
32
204
2.53
2.55
12.7
6.7
1.21
1.20
mmol/l
0.26
27
179
6
159
0.29
2.48
5.3
3.8
—
—
—
0
0
10
34
3.40
2.44
4.3
3.0
7.43
7.40
ph
—
10
27
29
189
2.24
2.05
8.6
5.4
0.04
0.04
e9/l
0.03
24
155
29
189
2.24
2.05
8.6
5.3
0.66
0.62
e9/l
0.29
24
153
22
128
2.26
2.04
10.2
4.9
—
—
—
0
0
10
40
2.86
2.02
2.3
2.2
—
—
—
0
0
30
200
2.21
1.99
8.6
5.2
0.17
0.21
e9/l
0.78
25
162
14
70
2.38
1.80
3.6
2.7
11.92
11.83
umol/l
0.02
14
64
12
57
2.45
1.71
7.8
8.0
102.58
104.44
mmol/l
0.47
12
57
13
67
2.26
1.55
3.8
2.5
2.40
2.15
g/l
0.79
13
61
17
99
2.08
1.51
7.6
4.7
—
—
—
0
0
34
257
1.97
1.42
9.0
4.8
6.80
6.97
mmol/l
0.18
34
244
17
103
1.98
1.34
1.4
1.3
—
—
—
0
0
8
35
2.52
1.34
10.9
11.2
—
—
—
0
0
8
37
2.37
1.28
9.8
9.4
0.82
1.60
mmol/l
—
8
37
8
37
2.37
1.28
1.7
1.5
—
—
—
0
0
11
59
2.10
1.18
3.2
1.9
1.56
1.53
%
0.07
11
49
0
30
0.00
1.01
0.0
1.5
—
—
—
0
0
8
46
1.87
0.87
4.1
3.3
2.60
1.70
mmol/l
—
8
38
21
155
1.60
0.81
6.4
3.6
—
—
—
0
0
14
94
1.67
0.77
2.1
2.1
1.79
2.99
e6/l
1.12
14
82
35
397
0.62
0.73
4.5
5.5
1.40
1.36
mmol/l
0.19
30
363
13
90
1.60
0.63
8.4
3.4
25.77
548.75
ng/l
1.14
13
76
6
34
1.86
0.61
1.7
1.4
—
—
—
0
0
8
54
1.57
0.61
1.5
1.6
—
—
—
0
0
24
194
1.45
0.57
2.5
2.1
99.79
88.99
pmol/l
0.39
19
110
20
156
1.46
0.57
2.0
3.7
6.35
6.18
ph
—
10
82
15
111
1.50
0.55
3.8
3.2
—
—
—
0
0
10
67
1.61
0.54
3.5
1.5
—
—
—
0
0
7
46
1.60
0.51
1.4
2.8
5.81
11.69
ug/l
—
7
39
5
32
1.62
0.43
2.2
2.0
—
0.00
estimate
—
0
9
37
403
0.70
0.43
5.2
6.5
2.16
2.43
mmol/l
1.11
31
369
18
145
1.37
0.41
1.9
2.3
75.39
284.81
u/l
4.14
18
135
5
36
1.43
0.39
1.0
1.5
—
—
—
0
0
26
296
0.75
0.39
5.6
4.5
—
—
—
0
0
6
41
1.52
0.38
1.2
2.8
63.35
66.46
g/l
—
6
36
36
391
0.73
0.37
6.2
5.6
6.01
6.25
mmol/l
0.74
31
345
20
168
1.31
0.34
13.9
9.4
0.00
0.00
e9/l
0.50
15
129
7
52
1.40
0.33
1.7
1.2
—
—
—
0
0
18
150
1.31
0.32
3.4
2.9
0.64
0.79
ug/l
0.57
13
104
37
392
0.80
0.22
7.1
7.8
38.81
40.87
mmol/mol
0.89
31
362
0
11
0.00
0.21
0.0
1.2
—
151.74
—
0
11
0
11
0.00
0.21
0.0
1.6
—
—
—
0
0
0
10
0.00
0.21
0.0
1.3
—
0.87
—
0
10
0
10
0.00
0.21
0.0
1.6
—
565.60
—
0
10
0
14
0.00
0.20
0.0
1.2
—
—
—
0
0
26
283
0.83
0.19
6.7
4.2
5.04
1.92
ug/l
0.49
26
255
41
422
0.85
0.09
53.5
21.9
31.10
30.72
pg
0.54
41
415
41
422
0.85
0.09
53.8
22.0
223.46
229.52
e9/l
0.30
41
409
41
422
0.85
0.09
54.9
22.1
126.76
138.25
g/l
3.81
41
416
41
422
0.85
0.09
55.1
22.6
38.02
41.20
%
3.73
41
415
6
70
0.84
0.08
3.0
4.6
—
—
—
0
0
41
421
0.87
0.07
53.5
22.0
92.84
91.91
fl
0.48
41
414
41
409
1.01
0.00
46.4
18.9
137.80
139.76
mmol/l
2.83
41
400
40
397
1.04
0.00
28.6
13.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
7
0.00
-0.00
0.0
2.1
—
9.86
—
0
7
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.8
—
4.17
—
0
8
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
33.50
—
0
6
0
5
0.00
-0.00
0.0
1.4
—
2.08
—
0
5
0
9
0.00
-0.00
0.0
1.1
—
0.20
—
0
9
0
6
0.00
-0.00
0.0
1.2
—
15.35
—
0
6
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
4.1
—
10.31
—
0
7
0
8
0.00
-0.00
0.0
1.3
—
—
—
0
0

Mortality – FinRegistry

↥

This endpoint is excluded (different definition than used in FinnGen).

Relationships between endpoints

↥

Index endpoint: C3_PIRIFORMSINUS_WIDE – Malignant neoplasm of pyriform sinus, including Hilmo

GWS hits: -

This endpoint is excluded (different definition than used in FinnGen).